Author:
Tan Huaming,Han Xiuchen,Li Chao,Liu Wenli,Li Kanghong,Sheng Xiugui,Qi Shuying
Abstract
Ovarian cancer is a prevalent malignant tumor of the female reproductive system, often remaining concealed until it reaches an advanced stage. The standard treatment protocol includes cytoreductive surgery for ovarian cancer plus postoperative consolidation chemotherapy and maintenance therapy, although it carries a high recurrence rate. During the treatment period, chemotherapy can lead to bone marrow suppression, a condition known as Chemotherapy-Induced Myelosuppression (CIM). This suppression may necessitate dose reduction or chemotherapy treatment cycle delay. In severe cases, CIM can result in infection, fever, and potential harm to the patient’s life. Here, we report a case of a female patient with ovarian malignant tumor of biochemical recurrence who treated with chemotherapy combined with Trilaciclib, following previous perioperative chemotherapy with occurrence of severe CIM. It involves an intravenous injection of Trilaciclib before chemotherapy, which significantly abates the side effects of chemotherapy, reduces the occurrence of severe CIM, improves the patients’ quality of life, and decreases the economic burden of hospitalization. We hope that this retrospective analysis of the case may serve as a reference in preventing and treating severe CIM during chemotherapy in some patients with malignant tumors, ultimately benefiting more patients with tumors.
Reference19 articles.
1. NCCN clinical practice guidelines in oncology. Familial high-risk assessment: Breast, ovarian, and pancreatic, version 2. 2024,2023
2. Targeted drug conjugate systems for ovarian cancer chemotherapy;Ogundipe;BioMed Pharmacother,2023
3. Epithelial ovarian cancer: A five year review;Arnaoutoglou;Medicina (Kaunas),2023
4. Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up;Ferraro;Clin Biochem,2018
5. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study;Xie;Breast Cancer Res Treat,2018